Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
about
Flow Cytometry-Based Method To Detect Persisters in Candida albicans.Molecular mechanism of terbinafine resistance in Saccharomyces cerevisiaeEfficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in micePotent synergism of the combination of fluconazole and cyclosporine in Candida albicansMDR1-mediated drug resistance in Candida dubliniensisIn vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicansThe transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicansCandida albicans AGE3, the ortholog of the S. cerevisiae ARF-GAP-encoding gene GCS1, is required for hyphal growth and drug resistanceCalcium-activated-calcineurin reduces the In vitro and In vivo sensitivity of fluconazole to Candida albicans via Rta2pEvolution of microbial pathogens.Terbinafine resistance mediated by salicylate 1-monooxygenase in Aspergillus nidulans.Identification of microRNA-like RNAs in mycelial and yeast phases of the thermal dimorphic fungus Penicillium marneffeiGenetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter.Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative.Serum repressing efflux pump CDR1 in Candida albicans.A novel polyamide SL-A92 as a potential fungal resistance blocker: synthesis and bioactivities in Candida albicans.TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2.The amino acid residues of transmembrane helix 5 of multidrug resistance protein CaCdr1p of Candida albicans are involved in substrate specificity and drug transportFluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae.Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.Unexpected Transcripts in Tn7 orf19.2646 C. albicans Mutant Lead to Low Fungal Burden Phenotype In vivoFluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrataDistinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicansInfluence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans.Drug-induced regulation of the MDR1 promoter in Candida albicans.An ATP-driven efflux pump is a novel pathogenicity factor in rice blast diseaseAmino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance.Effects of azole antifungal drugs on the transition from yeast cells to hyphae in susceptible and resistant isolates of the pathogenic yeast Candida albicans.Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patientsAntagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agentsAccumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates.The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.Proton-pumping-ATPase-targeted antifungal activity of a novel conjugated styryl ketone.Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole.Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750
P2860
Q27324379-390A137A-8642-4F78-A89E-A2BB9A5652DFQ27939054-17E4F982-279F-48B4-BCF1-8B24DC09FBCCQ28344293-AA3F5EC4-7A9B-4078-89C8-C37690A7A062Q28344597-44DFCB64-D3E9-4A77-BB38-08D19A4C2BA8Q28364120-DD740908-9B81-42CE-BB9B-E367BBA829BDQ28379512-AF004B11-585A-4D5E-895E-BBD0EA0C4EAEQ28469241-F72A92C4-E60E-4B22-AFC9-10AE6D4F3363Q28469346-C34B8E5A-4347-4670-8485-2D94BF27C9B3Q28475025-8E266149-CC90-4AB5-B56A-8F0184FB550CQ28484616-09C06FDB-409E-4EB8-99E0-8934F9AFEA56Q30599966-83685FB9-54D6-4B0E-99FD-E96F166C9BB4Q31108109-49E8B6AD-5089-452C-91F2-7A06C32FDDDBQ31134211-38BB0E17-5566-4E43-87D8-0AA3FA3F36BFQ32133639-43CC7DC5-437C-434D-989F-54D6C28B68FFQ33200348-1E01789F-9EE5-41B5-B77D-30BE5FB71600Q33250096-85C80BBB-B3E7-48DE-98E1-17666F8F380EQ33557539-6E672FAC-9283-48BD-A0F3-C175CD3DC006Q33559776-D7EFF41A-3AB6-4866-AFE3-4B85A476E6FBQ33560121-78E91F56-7C25-4F07-85C0-842AA59BCF25Q33593689-4A3B3AAC-C4F1-4B84-912D-D9BEB371A271Q33634941-E814B9D2-5133-47AA-BA93-E75FAE780ABEQ33689421-0771F12B-BFEC-4A86-B908-C196120101FFQ33690201-6AEA488E-E961-4B50-A66F-70C2CF4C4005Q33694125-FA897B34-1B90-426F-9479-1AA737D2539CQ33701491-8BBFA105-1AE9-4F52-9374-8647EC58DDB7Q33721804-0CB05DB6-2B71-4AFC-A8DC-F5C2D75D13EAQ33749111-4F5A3A4B-4350-4C7F-9406-6EED2FBCB960Q33859372-80D94823-8C26-494C-BFDF-3E250DE5E662Q33883085-96B18E78-A5A5-4DA5-B045-A1C2C4CBE5E1Q33883805-4C328C84-546A-47F6-9F78-3EAF24F92F1DQ33890356-4F5088A3-63C1-4117-AD2F-FB5E40117C07Q33940714-9EE169CF-BAC3-4051-8C95-CA119B4FF327Q33976591-8C4BA81A-5F16-4978-9C40-F47FC226838EQ33977103-AD2CAD34-CA74-4A6F-B79E-719BB63D00B9Q33977417-B0D36F3C-1F2B-49AC-852E-6D7642D86075Q33978021-6E8CA31D-813A-4EA6-9637-37C502F0D9FCQ33978099-903480CE-132B-4916-838F-684C87914A64Q33978287-31CA70FE-1F29-4708-8E07-9FE92BD18752Q33979398-424A242E-9465-4079-8DF2-0445BAC4950CQ33979724-51C9FBE0-30AA-4911-A21D-24CB5631DC3C
P2860
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
description
1996 nî lūn-bûn
@nan
1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Susceptibilities of Candida al ...... and other metabolic inhibitors
@ast
Susceptibilities of Candida al ...... and other metabolic inhibitors
@en
type
label
Susceptibilities of Candida al ...... and other metabolic inhibitors
@ast
Susceptibilities of Candida al ...... and other metabolic inhibitors
@en
prefLabel
Susceptibilities of Candida al ...... and other metabolic inhibitors
@ast
Susceptibilities of Candida al ...... and other metabolic inhibitors
@en
P2093
P2860
P356
P1476
Susceptibilities of Candida al ...... and other metabolic inhibitors
@en
P2093
P2860
P304
P356
10.1128/AAC.40.10.2300
P407
P577
1996-10-01T00:00:00Z